Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1969 2
1970 2
1971 2
1972 3
1973 2
1975 2
1976 1
1977 2
1978 1
1979 1
1980 4
1981 1
1982 3
1983 4
1984 1
1985 1
1986 1
1987 3
1989 1
1990 5
1991 4
1992 1
1993 1
1994 4
1995 4
1996 3
1997 5
1998 6
1999 2
2000 2
2001 3
2002 7
2003 1
2004 8
2005 5
2006 3
2007 14
2008 8
2009 12
2010 7
2011 13
2012 13
2013 14
2014 11
2015 14
2016 21
2017 14
2018 19
2019 19
2020 21
2021 28
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

307 results
Results by year
Filters applied: . Clear all
Page 1
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Kappos L, et al. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Lancet. 2018. PMID: 29576505 Clinical Trial.
METHODS: This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 hospital clinics and specialised multiple sclerosis centres in 31 countries. ...One patient did not sign the consent form, and five patients did not receive study drug …
METHODS: This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 hospital clinics and specialised multi …
Role of Viruses in the Pathogenesis of Multiple Sclerosis.
Tarlinton RE, Martynova E, Rizvanov AA, Khaiboullina S, Verma S. Tarlinton RE, et al. Viruses. 2020 Jun 13;12(6):643. doi: 10.3390/v12060643. Viruses. 2020. PMID: 32545816 Free PMC article. Review.
Multiple sclerosis (MS) is an immune inflammatory disease, where the underlying etiological cause remains elusive. ...Several viruses have been proposed as potential triggering agents, including Epstein-Barr virus, human herpesvirus 6, varicella …
Multiple sclerosis (MS) is an immune inflammatory disease, where the underlying etiological cause remains elusive. ...Several …
Vaccines in Multiple Sclerosis.
Williamson EM, Chahin S, Berger JR. Williamson EM, et al. Curr Neurol Neurosci Rep. 2016 Apr;16(4):36. doi: 10.1007/s11910-016-0637-6. Curr Neurol Neurosci Rep. 2016. PMID: 26922172 Review.
There are several unique considerations with respect to vaccination in the multiple sclerosis (MS) population. First, there has been concern that vaccination may trigger or aggravate the disease. ...
There are several unique considerations with respect to vaccination in the multiple sclerosis (MS) population. First, there ha …
[Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation].
Winkelmann A, Löbermann M, Zettl UK. Winkelmann A, et al. Nervenarzt. 2019 Dec;90(12):1254-1260. doi: 10.1007/s00115-019-00806-x. Nervenarzt. 2019. PMID: 31531686 Review. German.
In patients with multiple sclerosis (MS) primary varicella zoster virus (VZV) infections (chickenpox) or reactivation (shingles, herpes zoster) pose a particular challenge for neurologists and physicians in everyday clinical practice. ...
In patients with multiple sclerosis (MS) primary varicella zoster virus (VZV) infections (chickenpox) or reactiv …
Systemic diseases and the cornea.
Shah R, Amador C, Tormanen K, Ghiam S, Saghizadeh M, Arumugaswami V, Kumar A, Kramerov AA, Ljubimov AV. Shah R, et al. Exp Eye Res. 2021 Mar;204:108455. doi: 10.1016/j.exer.2021.108455. Epub 2021 Jan 21. Exp Eye Res. 2021. PMID: 33485845 Free PMC article. Review.
These include endocrine disorders (diabetes, Graves' disease, Addison's disease, hyperparathyroidism), infections with viruses (SARS-CoV-2, herpes simplex, varicella zoster, HTLV-1, Epstein-Barr virus) and bacteria (tuberculosis, syphilis and Pseudomonas aeruginosa), autoi …
These include endocrine disorders (diabetes, Graves' disease, Addison's disease, hyperparathyroidism), infections with viruses (SARS-CoV-2, …
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Cohen JA, et al. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Free article. Clinical Trial.
BACKGROUND: Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on imaging in a phase 2 study involving patients with multiple sclerosis. METHODS: In this 12-mon …
BACKGROUND: Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes, showed clini …
Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?
Witman Tsur S, Adrian Zaher E, Tsur M, Kania K, Kalinowska-Łyszczarz A. Witman Tsur S, et al. Int J Mol Sci. 2021 Apr 8;22(8):3859. doi: 10.3390/ijms22083859. Int J Mol Sci. 2021. PMID: 33917860 Free PMC article. Review.
Vaccines work by stimulating the immune system, and their immunogenicity is key in achieving protection against specific pathogens. Questions have been raised whether in Multiple Sclerosis (MS) patients they could induce disease exacerbation and whether vaccines cou …
Vaccines work by stimulating the immune system, and their immunogenicity is key in achieving protection against specific pathogens. Question …
Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab.
Rapisarda L, Valentino P, Barone S, Torti C, La Gamba V, Fortunato F, Sammarra I, Gambardella A. Rapisarda L, et al. Clin Immunol. 2021 Feb;223:108554. doi: 10.1016/j.clim.2020.108554. Epub 2020 Aug 8. Clin Immunol. 2021. PMID: 32777270
Ocrelizumab is a novel humanized anti-CD20 antibody used for treatment of relapsing remitting and primary progressive multiple sclerosis with evidence of inflammatory activity. Guidelines suggest assessing vaccination status and eventually vaccinate patients with …
Ocrelizumab is a novel humanized anti-CD20 antibody used for treatment of relapsing remitting and primary progressive multiple scl …
Multiple sclerosis and varicella zoster virus infection: a review.
Marrie RA, Wolfson C. Marrie RA, et al. Epidemiol Infect. 2001 Oct;127(2):315-25. doi: 10.1017/s0950268801005891. Epidemiol Infect. 2001. PMID: 11693509 Free PMC article. Review.
We have evaluated the epidemiological evidence for an aetiological role of varicella zoster virus (VZV) infection in the development of multiple sclerosis (MS). ...The five studies with the best methodology failed to show an increased risk of MS associated wi …
We have evaluated the epidemiological evidence for an aetiological role of varicella zoster virus (VZV) infection in the development …
The varicella-zoster virus and multiple sclerosis.
Ross RT. Ross RT. J Clin Epidemiol. 1998 Jul;51(7):533-5. doi: 10.1016/s0895-4356(98)00030-4. J Clin Epidemiol. 1998. PMID: 9674659 Review.
This article is a review of the evidence suggesting a unique relationship between the varicella-zoster virus (as a possible antigen or antigen mimic) and multiple sclerosis (MS). Both MS and varicella have increased prevalences in temperate zones and b …
This article is a review of the evidence suggesting a unique relationship between the varicella-zoster virus (as a possible antigen o …
307 results